Duygu Özkan Yaşargün
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Duygu Özkan Yaşargün has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Aysegul Ozyilmaz
Düzce Atatürk State Hospital, Department of Neurology, Düzce, Turkey
1 shared publicationAyça Simay Ersöz
University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Neurology, Istanbul, Türkiye
1 shared publication- Ayça Simay Ersöz
University of Health Sciences
1 shared publication Cemile Handan Misirli
Haydarpaşa Numune Education and Research Hospital, Department of Neurology, İstanbul, Turkey
1 shared publication- Devran Süer
Department of Neurology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkiye
1 shared publication - Ece Akbayir
Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1911231
From seropositivity to neurosyphilis: clinical spectrum and diagnostic classification in hospitalized neurology patients: a 16-year retrospective study
Background: Neurosyphilis remains a diagnostic challenge because of its heterogeneous neurological manifestations and the absence of a universally accepted diagnostic gold standard. Diagnostic categories such as confirmed and probable neurosyphilis may help stratify syphilis-seropositive patients according to clinical and cerebrospinal fluid findings. This study aimed to evaluate syphilis seropositivity among hospitalized neurology patients and to compare clinical, radiological, and discharge neurological characteristics across diagnostic groups. Methods: This single-center retrospective observational study included adult patients hospitalized in the neurology ward between January 2010 and January 2026 who were identified as having positive serum treponemal serology. Patients were classified as confirmed neurosyphilis, probable neurosyphilis, or non-neurosyphilis seropositivity. Results: Among 9,172 hospitalized neurology patients who underwent serum TPHA testing during the study period, 25 eligible patients with syphilis seropositivity were included in the analysis. Ten patients were classified as confirmed neurosyphilis, five as probable neurosyphilis, and ten as non-neurosyphilis seropositivity. Age, sex distribution, vascular ischemia on admission, HIV status, and CT angiography vascular involvement did not differ significantly among the groups. MRI findings suggestive of neurosyphilitic involvement and positive neurological examination at discharge differed significantly among the diagnostic groups (both p = 0.001). Pairwise comparisons showed that these differences were significant only between the confirmed neurosyphilis and non-neurosyphilis seropositivity groups. Conclusion: Although syphilis seropositivity was uncommon among hospitalized neurology patients, a substantial proportion (60%) of seropositive individuals fulfilled the predefined criteria for confirmed or probable neurosyphilis. Our findings demonstrate that syphilis seropositivity should not be considered synonymous with neurosyphilis and highlight the importance of a comprehensive diagnostic evaluation integrating clinical presentation, cerebrospinal fluid findings, and neuroimaging. Syphilis testing remains a crucial component in the diagnostic evaluation of unexplained neurological syndromes in contemporary practice.
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1911231
Open AccessFrom seropositivity to neurosyphilis: clinical spectrum and diagnostic classification in hospitalized neurology patients: a 16-year retrospective study
Background: Neurosyphilis remains a diagnostic challenge because of its heterogeneous neurological manifestations and the absence of a universally accepted diagnostic gold standard. Diagnostic categories such as confirmed and probable neurosyphilis may help stratify syphilis-seropositive patients according to clinical and cerebrospinal fluid findings. This study aimed to evaluate syphilis seropositivity among hospitalized neurology patients and to compare clinical, radiological, and discharge neurological characteristics across diagnostic groups. Methods: This single-center retrospective observational study included adult patients hospitalized in the neurology ward between January 2010 and January 2026 who were identified as having positive serum treponemal serology. Patients were classified as confirmed neurosyphilis, probable neurosyphilis, or non-neurosyphilis seropositivity. Results: Among 9,172 hospitalized neurology patients who underwent serum TPHA testing during the study period, 25 eligible patients with syphilis seropositivity were included in the analysis. Ten patients were classified as confirmed neurosyphilis, five as probable neurosyphilis, and ten as non-neurosyphilis seropositivity. Age, sex distribution, vascular ischemia on admission, HIV status, and CT angiography vascular involvement did not differ significantly among the groups. MRI findings suggestive of neurosyphilitic involvement and positive neurological examination at discharge differed significantly among the diagnostic groups (both p = 0.001). Pairwise comparisons showed that these differences were significant only between the confirmed neurosyphilis and non-neurosyphilis seropositivity groups. Conclusion: Although syphilis seropositivity was uncommon among hospitalized neurology patients, a substantial proportion (60%) of seropositive individuals fulfilled the predefined criteria for confirmed or probable neurosyphilis. Our findings demonstrate that syphilis seropositivity should not be considered synonymous with neurosyphilis and highlight the importance of a comprehensive diagnostic evaluation integrating clinical presentation, cerebrospinal fluid findings, and neuroimaging. Syphilis testing remains a crucial component in the diagnostic evaluation of unexplained neurological syndromes in contemporary practice.
- Open Access
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5121
From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing—Remitting Multiple Sclerosis
Background/Objectives: Cladribine is a high-efficacy immune reconstitution therapy for relapsing multiple sclerosis, but additional real-world data remain valuable, particularly from single-center cohorts with combined clinical, radiological, and laboratory follow-up. This study aimed to evaluate the 24-month effectiveness and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS), with a particular focus on no evidence of disease activity (NEDA-3) and lymphopenia. Methods: This retrospective single-center observational cohort study included adults with RRMS treated with cladribine who had at least 24 months of clinical and MRI follow-up. NEDA-3 was defined as the absence of clinical relapses, disability progression, and MRI activity. Brain MRI was performed at 6, 12, and 24 months. Absolute lymphocyte counts were monitored longitudinally, and lymphopenia was graded according to standard criteria. Results: A total of 71 patients were included. NEDA-3 was achieved in 61 patients (85.9%) at 12 months and 50 patients (70.4%) at 24 months. No demographic or baseline clinical variable was independently associated with NEDA-3 at either time point. Lymphopenia occurred in 53 patients (74.6%), including grade 1 in 14 (19.7%), grade 2 in 23 (32.4%), grade 3 in 14 (19.7%), and grade 4 in 2 (2.8%). One patient developed herpes zoster infection during follow-up. Conclusions: Cladribine demonstrated durable effectiveness and a manageable safety profile over 24 months in a real-world RRMS population. The close alignment between our findings and those reported in pivotal clinical trials underscores the external validity of cladribine efficacy beyond controlled study environments. These data provide valuable real-world evidence bridging the gap between controlled research settings and everyday patient care, thereby strengthening the evidence base for cladribine in contemporary MS management.
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5121
Open AccessFrom Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing—Remitting Multiple Sclerosis
Background/Objectives: Cladribine is a high-efficacy immune reconstitution therapy for relapsing multiple sclerosis, but additional real-world data remain valuable, particularly from single-center cohorts with combined clinical, radiological, and laboratory follow-up. This study aimed to evaluate the 24-month effectiveness and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS), with a particular focus on no evidence of disease activity (NEDA-3) and lymphopenia. Methods: This retrospective single-center observational cohort study included adults with RRMS treated with cladribine who had at least 24 months of clinical and MRI follow-up. NEDA-3 was defined as the absence of clinical relapses, disability progression, and MRI activity. Brain MRI was performed at 6, 12, and 24 months. Absolute lymphocyte counts were monitored longitudinally, and lymphopenia was graded according to standard criteria. Results: A total of 71 patients were included. NEDA-3 was achieved in 61 patients (85.9%) at 12 months and 50 patients (70.4%) at 24 months. No demographic or baseline clinical variable was independently associated with NEDA-3 at either time point. Lymphopenia occurred in 53 patients (74.6%), including grade 1 in 14 (19.7%), grade 2 in 23 (32.4%), grade 3 in 14 (19.7%), and grade 4 in 2 (2.8%). One patient developed herpes zoster infection during follow-up. Conclusions: Cladribine demonstrated durable effectiveness and a manageable safety profile over 24 months in a real-world RRMS population. The close alignment between our findings and those reported in pivotal clinical trials underscores the external validity of cladribine efficacy beyond controlled study environments. These data provide valuable real-world evidence bridging the gap between controlled research settings and everyday patient care, thereby strengthening the evidence base for cladribine in contemporary MS management.
- Open Access
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1122-1129
Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis
Background/aim: Patients with multiple sclerosis (MS) may present with a rapidly disabling clinical course in the first few years of disease. It is imperative to find biomarkers to predict patients with aggressive MS (AMS) and have an opportunity to prevent disability accumulation through appropriate treatment strategies. Our aim was to explore the prognostic value of neurofilament light chain (NFL) and brain-derived neurotrophic factor (BDNF) levels in cerebrospinal fluid (CSF) obtained in the early stages of MS. Materials and methods: Relapsing-remitting multiple sclerosis (RRMS) patients presenting with first-time attacks were screened, of which 26 fulfilled AMS criteria in the 3-year follow-up period. In addition, 27 age/sex-matched RRMS patients without AMS (non- AMS) were included. Baseline NFL and BDNF levels were measured in CSF obtained during the remission period following the first MS attack. Disease activity was monitored for 3 years by periodic expanded disability status scale (EDSS), cranial-spinal MRI assessments, and no evidence of disease activity (NEDA)-3 was determined. Results: AMS patients showed significantly higher attack numbers, EDSS scores, MRI lesions, and baseline NFL levels compared to non-AMS patients. Baseline BDNF levels were significantly lower than in non-AMS patients. NFL/BDNF levels were correlated with number of attacks and/or EDSS scores at the third year follow-up. Patients with NEDA-3 showed significantly lower baseline NFL and higher BDNF levels than those without NEDA-3. Receiver operating characteristic curve analysis showed the highest specificity for CSF BDNF measurements in predicting AMS conversion. Conclusion: Baseline NFL and BDNF levels effectively predict the development of AMS emerging early in the course of MS. Combined use of these molecular markers with MRI results may enable early diagnosis and appropriate therapeutic intervention of AMS.
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1122-1129
Open AccessBaseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis
Background/aim: Patients with multiple sclerosis (MS) may present with a rapidly disabling clinical course in the first few years of disease. It is imperative to find biomarkers to predict patients with aggressive MS (AMS) and have an opportunity to prevent disability accumulation through appropriate treatment strategies. Our aim was to explore the prognostic value of neurofilament light chain (NFL) and brain-derived neurotrophic factor (BDNF) levels in cerebrospinal fluid (CSF) obtained in the early stages of MS. Materials and methods: Relapsing-remitting multiple sclerosis (RRMS) patients presenting with first-time attacks were screened, of which 26 fulfilled AMS criteria in the 3-year follow-up period. In addition, 27 age/sex-matched RRMS patients without AMS (non- AMS) were included. Baseline NFL and BDNF levels were measured in CSF obtained during the remission period following the first MS attack. Disease activity was monitored for 3 years by periodic expanded disability status scale (EDSS), cranial-spinal MRI assessments, and no evidence of disease activity (NEDA)-3 was determined. Results: AMS patients showed significantly higher attack numbers, EDSS scores, MRI lesions, and baseline NFL levels compared to non-AMS patients. Baseline BDNF levels were significantly lower than in non-AMS patients. NFL/BDNF levels were correlated with number of attacks and/or EDSS scores at the third year follow-up. Patients with NEDA-3 showed significantly lower baseline NFL and higher BDNF levels than those without NEDA-3. Receiver operating characteristic curve analysis showed the highest specificity for CSF BDNF measurements in predicting AMS conversion. Conclusion: Baseline NFL and BDNF levels effectively predict the development of AMS emerging early in the course of MS. Combined use of these molecular markers with MRI results may enable early diagnosis and appropriate therapeutic intervention of AMS.
- 1 January 2025
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 62 (4) , 354-359
EFFICACY OF INTRAVENOUS METHYLPREDNISOLONE VS INTRAVENOUS METHYLPREDNISOLONE+PLASMAPHERESİS IN NMOSD ATTACKS
Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating autoimmune condition that, without timely intervention, can lead to severe disability or even death. Neuromyelitis optica spectrum disorder is an inflammatory disease of the central nervous system characterized by severe attacks such as optic neuritis and transverse myelitis. This study compared the short- and long-term effects of high-dose intravenous methylprednisolone (IVMP) and IVMP+plasma exchange (PLEX) treatment regimens. The study evaluated changes in patients’ Expanded Disability Status Scale (EDSS) scores over a six-month follow-up period by using different ANOVA and linear regression methods. Both IVMP and IVMP+PLEX treatments resulted in clinical improvement, with the addition of PLEX showing a more significant reduction in EDSS scores, particularly during the long follow-up period. Moreover, seropositive patients (AQP4/MOG-IgG positive) demonstrated a better response to treatment. Age and baseline EDSS scores were identified as key factors influencing post-treatment improvement. Our results suggest that the addition of PLEX to IVMP treatment might be suitable especially for severe NMOSD attacks.
- 1 January 2025
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 62 (4) , 354-359
EFFICACY OF INTRAVENOUS METHYLPREDNISOLONE VS INTRAVENOUS METHYLPREDNISOLONE+PLASMAPHERESİS IN NMOSD ATTACKS
Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating autoimmune condition that, without timely intervention, can lead to severe disability or even death. Neuromyelitis optica spectrum disorder is an inflammatory disease of the central nervous system characterized by severe attacks such as optic neuritis and transverse myelitis. This study compared the short- and long-term effects of high-dose intravenous methylprednisolone (IVMP) and IVMP+plasma exchange (PLEX) treatment regimens. The study evaluated changes in patients’ Expanded Disability Status Scale (EDSS) scores over a six-month follow-up period by using different ANOVA and linear regression methods. Both IVMP and IVMP+PLEX treatments resulted in clinical improvement, with the addition of PLEX showing a more significant reduction in EDSS scores, particularly during the long follow-up period. Moreover, seropositive patients (AQP4/MOG-IgG positive) demonstrated a better response to treatment. Age and baseline EDSS scores were identified as key factors influencing post-treatment improvement. Our results suggest that the addition of PLEX to IVMP treatment might be suitable especially for severe NMOSD attacks.
- 1 June 2018
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 55 (2) , 135-139
Correlation of Electroencephalography and Magnetic Resonance Imaging in Patients with Mesial Temporal Sclerosis
Introduction: To determine the lateralization of lesion by non-invasive methods through correlation of cranial magnetic resonance imaging (MRI) and electroencephalography (EEG) findings in patients with mesial temporal sclerosis (MTS). Methods: This study included 40 patients (Age range, 19 to 55 years) among 1850 patients who were attending outpatient epilepsy clinic of Haydarpasa Numune Hospital between the years 2000 and 2013. Exclusion criteria were surgery due to MTS, metabolic and systemic disorders, indefinite diagnosis, and inadequate MRI and EEG evaluations. Results: EEG findings were within normal limits in 10 (25%) patients who had MTS on MRI. Of these, 5 patients had right MTS, 4 had left MTS, and one patient had bilateral MTS. Conclusion: In this study, we used electrophysiological diagnostic methods together with MR imaging to determine epileptogenic localization in patients with MTS. We suggest that, when correlated with MRI. EEG is a non-invasive and easy method to identify lateralization findings.
- 1 June 2018
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 55 (2) , 135-139
Correlation of Electroencephalography and Magnetic Resonance Imaging in Patients with Mesial Temporal Sclerosis
Introduction: To determine the lateralization of lesion by non-invasive methods through correlation of cranial magnetic resonance imaging (MRI) and electroencephalography (EEG) findings in patients with mesial temporal sclerosis (MTS). Methods: This study included 40 patients (Age range, 19 to 55 years) among 1850 patients who were attending outpatient epilepsy clinic of Haydarpasa Numune Hospital between the years 2000 and 2013. Exclusion criteria were surgery due to MTS, metabolic and systemic disorders, indefinite diagnosis, and inadequate MRI and EEG evaluations. Results: EEG findings were within normal limits in 10 (25%) patients who had MTS on MRI. Of these, 5 patients had right MTS, 4 had left MTS, and one patient had bilateral MTS. Conclusion: In this study, we used electrophysiological diagnostic methods together with MR imaging to determine epileptogenic localization in patients with MTS. We suggest that, when correlated with MRI. EEG is a non-invasive and easy method to identify lateralization findings.